QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

XFOR

QT71X4 Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.22
+0.17+4.20%
OverviewShort InterestFilings
XFORQT71X4 Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
4.22+4.20%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-4.54
Insider Own-
Shs Outstand-
Perf Week8.76%
Market Cap381.99MForward P/E-EPS next Y-0.80Insider Trans-Shs Float-Perf Month15.93%
Enterprise Value242.34MPEG0.00EPS next Q-0.19Inst Own-Short Float-Perf Quarter1.20%
Income-74488980.00P/S42.38EPS this Y83.92%Inst Trans-Short Ratio-Perf Half Y13.75%
Sales9.01MP/B3.04EPS next Y-9.25%ROA-36.90%Short Interest-Perf YTD5.50%
Book/sh-P/C-EPS next 5Y-ROE-94.90%52W High4.83 -12.63%Perf Year54.01%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-39.53%52W Low1.35 212.59%Perf 3Y-
Dividend Est.-EV/EBITDA-2.70Sales past 3/5Y- 63.45%Gross Margin79.44%Volatility2.44% 3.62%Perf 5Y-
Dividend TTM-EV/Sales26.88EPS Y/Y TTM18.78%Oper. Margin-1084.38%ATR (14)0.22Perf 10Y-
Dividend Ex-Date-Quick Ratio9.98Sales Y/Y TTM233.33%Profit Margin-1106.30%RSI (14)57.08Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.18EPS Q/Q-SMA205.39%Beta2.30Target Price12.00
Payout0.00%Debt/Eq0.46Sales Q/Q-89.66%SMA503.02%Rel Volume2.23Prev Close4.05
Employees143LT Debt/Eq0.41EarningsAug 06SMA20012.11%Avg Volume389.17KPrice4.22
IPO DateNov 16, 2017Option/ShortYes / YesEPS/Sales Surpr.20.00% -33.33%Net Debt/EBITDA1.55Volume866,227Change4.20%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26InitiatedLeerinkOutperform$12
Mar-09-26InitiatedGuggenheimBuy$12
Dec-05-25ReiteratedStifel Nicolaus$7.50 → $10
Nov-05-25ReiteratedStifel Nicolaus$9.00 → $7.50
Aug-29-25ReiteratedStifel Nicolaus$30 → $9.00
Aug-13-25ReiteratedH.C. WainwrightOutperform$7.00 → $3.50
Dec-12-23DowngradeB. Riley SecuritiesBuy → Neutral
Dec-22-22ReiteratedCantor FitzgeraldOverweight$3.00
Nov-30-22ReiteratedH.C. WainwrightOutperform$5.00
Dec-09-19UpgradeCitigroupNeutral → Buy
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue10353
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A161
Gross Profit6292
Selling, General and Administrative Excl. Other364462
Research and Development687282
Other Operating Expense10-106
Operating Income-98-87-36
Interest Expense899
Unusual Expense
———
Non-Operating Income (Expense)-7-17-8
Net Income Before Taxes-100-79-37
Income Taxes
000
Consolidated Net Income-100-79-37
Net Income From Continuing Operations-100-79-37
Net Income-100-79-37
EPS (Recurring)-4.54-1.87-5.59
EPS (Basic, Before Extraordinaries)-4.54-1.87-5.59
EPS (Diluted)-4.54-1.87-5.59
EBITDA-90-69-28
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio53.174.80—
Gross Margin60.0082.8666.67
Operating Margin-980.00-248.57-1,200.00
Net Margin-1,000.00-225.71-1,233.33
Shares Outstanding126427
Market Capitalization532168—
Operating Lease Expense
———
Insider Trading Volume
$4.34$4.08$3.81$3.54$3.28● Close Price0.00K62.50K125.00K187.50K250.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
KIRSKE DAVIDChief Financial OfficerMay 12 '26Sale4.2916,96172,820176,293May 13 12:00 AM
Craig Adam RExecutive ChairmanOct 23 '25Buy2.9086,206249,997376,087Oct 27 12:00 AM
Baldry MarkChief Commercial OfficerMay 16 '25Buy2.481,0322,56125,337May 20 12:00 AM
Baldry MarkChief Commercial OfficerNov 15 '24Buy0.3413,4044,598129,173Feb 14 12:00 AM
Baldry MarkChief Commercial OfficerMay 17 '24Buy0.6821,64614,654115,769Feb 14 12:00 AM
Baldry MarkChief Commercial OfficerJan 24 '25Sale0.4529,15913,24194,123Jan 27 12:00 AM
Ragan PaulaPresident and CEOJan 24 '25Sale0.4576,47334,7191,087,386Jan 27 12:00 AM
Arbet-Engels ChristopheChief Medical OfficerJan 24 '25Sale0.4511,6245,28414,207Jan 27 12:00 AM
Mostafa Adam S.Chief Financial OfficerJan 24 '25Sale0.4574,77333,9470Jan 27 12:00 AM
DiBiase MaryChief Operating OfficerJan 24 '25Sale0.4522,25810,094490,980Jan 27 12:00 AM
Ragan PaulaPresident and CEONov 15 '24Sale0.3931,89712,583993,919Nov 19 12:00 AM
Ragan PaulaPresident and CEOOct 15 '24Sale0.5631,89717,9261,025,816Oct 16 12:00 AM
Ragan PaulaPresident and CEOOct 07 '24Sale0.55239,436131,5221,057,713Oct 08 12:00 AM
Mostafa Adam S.Chief Financial OfficerOct 07 '24Sale0.55230,645126,9010Oct 08 12:00 AM
Taveras ArthurChief Scientific OfficerOct 07 '24Sale0.5676,92043,306388,026Oct 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR